motexafin lutetium profile

motexafin lutetium: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3081907
MeSH ID	M0269040

Synonym
unii-0a85bj22l6
0a85bj22l6 ,
pci-0123
antrin
motexafin lutetium
lu-tex
lutetium texaphyrin
nsc-695239
156436-90-7
bis(acetato-o)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-n(sup 1),n(sup 18),n(sup 23),n(sup 24),n(sup 25))-, hydrate, (pb-7-11-233'2'4)
motexafin lutetium [usan]
lutetium, bis(acetato-kappao)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-kappan(sup 1),kappan(sup 18),kappan(sup 23),kappan(sup 24),kappan(sup 25
lutetium, bis(acetato-kappao)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-kappan1,kappan18,kappan23,kappan24,kappan25)-, hydrate, (pb-7-11-233'2'4
fp-lp1
nsc 695239
lutetium, bis(acetato-o)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-n1,n18,n23,n24,n25)-, hydrate, (pb-7-11-233'2'4)-
lu texaphyrin
FT-0672544
motexafin lutetium [mi]
motexafin lutetium [who-dd]
Q6917197

Excerpt	Reference	Relevance
"Motexafin lutetium (MLu; Antrin) is a photosensitizer that is taken up by atherosclerotic plaque and concentrated within macrophages and vascular smooth muscle cells. "	( Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Adelman, DC; Carroll, TE; Chou, TM; Fitzgerald, P; Forer, D; Herrmann, HC; Kereiakes, DJ; Kramer, P; Popma, J; Rogers, C; Shear, W; Shunk, KA; Simon, DI; Szyniszewski, AM; Wahr, D; Yeung, AC, 2003)	2.02
"Motexafin lutetium (Lu-Tex) is a photosensitizer that targets atheromatous plaque. "	( Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model. Hayase, M; Robbins, RC; Woodburn, KW; Yamaguchi, A, 2000)	1.99
"Motexafin lutetium is a photosensitizer that accumulates in atherosclerotic plaque and, after activation by far-red light, produces cytotoxic singlet oxygen. "	( Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Adelman, DC; Chen, Z; Rogers, C; Shi, C; Simon, DI; Woodburn, KW, 2001)	2.05
"Motexafin lutetium (Lu-Tex) is a photodynamic therapy (PDT) agent that localizes in atheromatous plaque in which it can be activated by far-red light. "	( Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease. Hayase, M; Hoyt, G; Robbins, RC; Woodburn, KW; Yamaguchi, A, 2001)	2.05
"Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. "	( In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. Busch, TM; Cheung, R; Griffin, GM; Hahn, SM; Kachur, A; Solonenko, M; Vulcan, T; Wang, HW; Yodh, AG; Zhu, TC, 2002)	1.99

Excerpt	Reference	Relevance
" All the measurements yield very similar pharmacokinetic curves."	( Fluorescence pharmacokinetics of Lutetium Texaphyrin (PCI-0123, Lu-Tex) in the skin and in healthy and tumoral hamster cheek-pouch mucosa. Monnier, P; Radu, A; van den Bergh, H; Wagnières, G; Zellweger, M, 2000)	0.31

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (22.22)	18.2507
2000's	33 (73.33)	29.6817
2010's	2 (4.44)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (20.41%)	5.53%
Reviews	5 (10.20%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (69.39%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I Study Photodynamic Therapy Using Lutrin (Lutetium Texaphyrin) in the Treatment of Patients With Cervical Intraepithelial Neoplasia [NCT00005808]	Phase 1	54 participants (Actual)	Interventional	2000-12-31	Terminated(stopped due to Administratively complete.)
Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies [NCT00087191]		30 participants (Actual)	Interventional	2004-05-31	Terminated(stopped due to Administratively complete.)
A Phase I Trial of Photodynamic Therapy With Lutetium Texaphyrin in Patients With Locally Recurrent Prostate Carcinoma [NCT00005067]	Phase 1	24 participants (Actual)	Interventional	2000-02-29	Terminated(stopped due to Administratively complete.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	2	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.02	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2	1	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
fluorescein Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.	2	1	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
dysprosium Dysprosium: An element of the rare earth family that has the atomic symbol Dy, atomic number 66, and atomic weight 162.50. Dysprosium is a silvery metal used primarily in the form of various salts.	2.02	1	0	f-block element atom; lanthanoid atom
lutetium Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.	4.63	6	1	d-block element atom; lanthanoid atom
argon Argon: A noble gas with the atomic symbol Ar, atomic number 18, and atomic weight 39.948. It is used in fluorescent tubes and wherever an inert atmosphere is desired and nitrogen cannot be used.	1.99	1	0	monoatomic argon; noble gas atom; p-block element atom	food packaging gas; neuroprotective agent
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.4	2	0	f-block element atom; lanthanoid atom
temoporfin temoporfin: used as PHOTOCHEMOTHERAPY	3.15	1	0
chlorin chlorin: RN given refers to parent cpd; structure. chlorin : A tetrapyrrole fundamental parent that is obtained by formal hydrogenation across the 2,3-double bond of porphyrin.	1.99	1	0
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	2	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
benzoporphyrin d benzoporphyrin D: C42H44N4O8, MW 732.821	2.4	2	0
motexafin gadolinium [no description available]	14.11	27	2
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	2	1	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2	1	0	benzenes; hydroxycoumarin; methyl ketone
texaphyrin texaphyrin: structure in first source. texaphyrin : A class of synthetic expanded porphyrins with a 22 pi-electron aromatic system. They are named after the state of Texas where these compounds were first synthesised.	2.02	1	0
chloroaluminum tetrasulfophthalocyanine chloroaluminum tetrasulfophthalocyanine: RN given refers to parent cpd	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Recrudescence [description not available]	3.43	1	1
Cancer of Prostate [description not available]	7.1	7	5
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	7.1	7	5
Benign Neoplasms [description not available]	5.23	4	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.23	4	1
Arteriosclerosis, Coronary [description not available]	5	3	1
Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts.	3.33	2	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	5	3	1
Breast Cancer [description not available]	8.39	1	1
Local Neoplasm Recurrence [description not available]	4.37	2	2
Breast Neoplasms Tumors or cancer of the human BREAST.	3.39	1	1
Animal Mammary Carcinoma [description not available]	2.7	3	0
Adenocarcinoma, Basal Cell [description not available]	4.88	4	2
Cancer of Pancreas [description not available]	2.02	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	4.88	4	2
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.02	1	0
Choroid Neovascularization [description not available]	4.31	4	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.42	2	0
Cirrhosis [description not available]	2.02	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.02	1	0
Cancer of Rectum [description not available]	2.03	1	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.03	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	4.09	3	1
Experimental Mammary Neoplasms [description not available]	2.39	2	0
EHS Tumor [description not available]	1.99	1	0
Experimental Neoplasms [description not available]	2.91	4	0
Malignant Melanoma [description not available]	1.99	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.99	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	3.83	4	0
Benign Neoplasms, Brain [description not available]	4.71	2	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	4.71	2	1
Carcinoma, Epidermoid [description not available]	2.4	2	0
Cancer of Ovary [description not available]	2	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.4	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2	1	0
Neovascularization, Optic Disc [description not available]	2	1	0
Retinal Neovascularization Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.	2	1	0
Age-Related Macular Degeneration [description not available]	3.79	2	0
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	3.79	2	0
Carcinoma, Intraepithelial [description not available]	2	1	0
Cancer of Mouth [description not available]	2	1	0
Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.	2	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	2	1	0
Extravascular Hemolysis [description not available]	2	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2	1	0
Sarcoma, Epithelioid [description not available]	2	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	2	1	0
Acquired Immune Deficiency Syndrome [description not available]	3.37	1	1
Kaposi Sarcoma [description not available]	3.37	1	1
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	3.37	1	1
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	3.37	1	1

motexafin lutetium

Description

Cross-References

Synonyms (21)

Research Excerpts

Overview

Pharmacokinetics

Research

Studies (45)

Market Indicators

Research Demand Index: 18.01

Study Types

Clinical Trials (3)

Trial Overview

motexafin lutetium

Description

Cross-References

Synonyms (21)

Research Excerpts

Overview

Pharmacokinetics

Research

Studies (45)

Market Indicators

Research Demand Index: 18.01

Study Types

Clinical Trials (3)

Trial Overview

Related Drugs (17)

Related Conditions (52)